In another study, it was shown that the activation of the PI3K pathway, independent of BCR/ABL, caused imatinib resistance in a group of resistant Ph + cells, including Ph + ALL cells, and targeting PI3K was effective in breaking imatinib resistance [36]. This evidence concerns the gene BCR and acute lymphoblastic leukemia.